Ziopharm Oncology to Announce Fourth Quarter and Full Year 2017 Year-end Financial Results and Host Conference Call on March ...
February 13 2018 - 7:15AM
Ziopharm Oncology, Inc. (Nasdaq:ZIOP), today announced that
management will host a conference call and webcast slide
presentation on Thursday, March 1, at 4:30 p.m. ET to provide a
corporate update and discuss financial results for the fourth
quarter and year ended Dec. 31, 2017.
The call can be accessed by dialing 1-844-309-0618
(U.S. and Canada) or 1-661-378-9465 (international). The passcode
for the conference call is 3782628. To access the slides and live
webcast or the subsequent archived recording, visit the "Investors
& Media" section of the Ziopharm website
at www.ziopharm.com. The webcast will be recorded and
available for replay on the Company's website for two weeks.
About Ziopharm Oncology,
Inc.
Ziopharm Oncology is a Boston-based biotechnology
company focused on development of next-generation immunotherapies
utilizing gene- and cell-based therapies to treat patients with
cancer. In partnership with Precigen Inc., a wholly-owned
subsidiary of Intrexon Corporation (NYSE:XON), Ziopharm is focused
on the development of two platform technologies designed to deliver
safe, effective and scalable cell- and viral-based therapies for
the treatment of multiple cancer types: Controlled IL-12 and
Sleeping Beauty for genetically modifying T cells. The Company’s
lead asset, Ad-RTS-hIL-12 plus veledimex, has demonstrated in
clinical trials the potential to control interleukin-12, leading to
an infiltration of T cells that fight brain cancer. The Company
also is advancing therapies using Sleeping Beauty, a non-viral
approach to genetically modify chimeric antigen receptor (CAR+) and
T-cell receptor (TCR+) T cells, which target specific antigens in
blood cancers and neoantigens solid tumors. Sleeping Beauty is
designed using the Company’s point-of-care technology, a shortened
manufacturing process which potentially can be developed as a
decentralized manufacturing process based in hospitals. These
programs are being advanced in collaboration with Precigen and with
MD Anderson Cancer Center, the National Cancer Institute and Merck
KGaA, Darmstadt, Germany.
Forward-Looking Disclaimer This
press release contains certain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended. Forward-looking statements are statements that
are not historical facts, and in some cases can be identified by
terms such as "may," "will," "could," "expects," "plans,"
"anticipates," and "believes." These statements include, but are
not limited to, statements regarding the Company’s business and
strategic plans, the Company’s ability to establish a
commercially-viable manufacturing approach as well as the progress
and timing of the development of the Company's research and
development programs, including its potential initiation of a first
in-human trial using its P-O-C manufacturing process. All such
statements are subject to certain risks and uncertainties, many of
which are difficult to predict and generally beyond the control of
the Company, that could cause actual results to differ materially
from those expressed in, or implied by, the forward-looking
statements. These risks and uncertainties include, but are not
limited to: changes in the Company’s financial condition and cash
needs, funding or other strategic opportunities that become
available to the Company, the Company's ability to finance its
operations and business initiatives and obtain funding for such
activities; whether chimeric antigen receptor T cell (CAR-T)
approaches, Ad-RTS-hIL-12, TCR and NK cell-based therapies, or any
of other product candidates will advance further in the preclinical
research or clinical trial process and whether and when, if at all,
they will receive final approval from the U.S. Food and Drug
Administration or equivalent foreign regulatory agencies and for
which indications; whether chimeric antigen receptor T cell (CAR-T)
approaches, Ad-RTS-hIL-12, TCR and NK cell-based therapies, and the
Company's other therapeutic products it develops will be
successfully marketed if approved; the strength and enforceability
of the Company's intellectual property rights; competition from
other pharmaceutical and biotechnology companies; as well as other
risk factors contained in the Company's periodic and interim
reports filed from time to time with the Securities and Exchange
Commission, including but not limited to, the risks and
uncertainties set forth in the "Risk Factors" section of the
Company's Quarterly Report on Form 10-Q for the quarter ended
September 30, 2017 and subsequent reports that the Company may file
with the Securities and Exchange Commission. Readers are cautioned
not to place undue reliance on these forward-looking statements
that speak only as of the date hereof, and the Company does not
undertake any obligation to revise and disseminate forward-looking
statements to reflect events or circumstances after the date
hereof, or to reflect the occurrence of or non-occurrence of any
events.
Contact:David ConnollyZiopharm
Oncology617-502-1881dconnolly@ziopharm.com
Intrexon (NASDAQ:XON)
Historical Stock Chart
From Aug 2024 to Sep 2024
Intrexon (NASDAQ:XON)
Historical Stock Chart
From Sep 2023 to Sep 2024